Carl Novina, MD, Ph.D., has been appointed as scientific advisor, Atossa Genetics Inc. a clinical-stage pharma company developing novel therapeutics and delivery methods for breast cancer. Dr. Novina is a leading researcher in the field of RNAi therapeutics. He is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He is currently the principal investigator of the Novina Lab a...